Xeris Biopharma expects full-year 2025 revenue above estimates

 

• Xeris Biopharma (XERS) expects full-year 2025 total revenue of $292M (vs. estimate of $287.42M), exceeding the guidance range of $285M-$290M and reflecting growth of 44% compared to the prior year.
• Q4 and full year 2025 Recorlev net revenue of $45M and $139M, respectively
• Recorlev, indicated for the treatment of endogenous Cushing’s syndrome, had preliminary net revenue of $45M in Q4 and $139M in 2025, respectively.
• Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia, grew revenue more than 13% compared to the prior year, while Keveyis, a therapy for primary periodic paralysis, finished the year with a growing patient base and a greater number of patients on therapy compared to year-end 2024.
• XERS +4% premarket at $7.50.

https://www.msn.com/en-us/money/companies/xeris-biopharma-expects-full-year-2025-revenue-above-estimates/ar-AA1TOOqJ